Related Experiment Video
Updated: Feb 3, 2026

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing
Kevin Shee1, Kristen E Muller2, Jonathan Marotti2
1Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon.
Abstract:
Historically, ductal carcinoma in situ (DCIS) of the breast has been managed aggressively with surgery and radiotherapy because of a risk of progression to invasive ductal carcinoma. However, this treatment paradigm has been challenged by overtreatment concerns and evidence that suggests that DCIS can be stratified according to risk of recurrence or risk of progression to invasive disease. Traditional methods of risk stratification include histologic grade and hormone receptor status. Recent technological advancements have enabled an era of precision medicine, where DCIS can be molecularly analyzed by tools, such as next-generation DNA and RNA sequencing, to identify molecular biomarkers for risk stratification. These findings have led to the development of tools such as the Oncotype DX Breast DCIS Score, a gene expression-based assay with the potential to prevent overtreatment in low-risk disease.
Related Concept Videos
Uncertainty in Measurement: Accuracy and Precision
Molecular Models
Microorganisms in Medicine and Therapeutics
Accuracy and Precision
Electrical Current
Molecular Compounds: Formulas and Nomenclature

